Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023

Provided By Globe Newswire

Last update: May 4, 2023

Updated clinical data from Phase 2 studies evaluating SRF388 in both liver and lung cancer expected in the second quarter of 2023

Projected cash runway guidance remains unchanged with funding into the third quarter of 2024